This unique series of four live, one-day meetings will provide expert reviews of the most meaningful and practice-changing data in the field of hematologic malignancies presented at ASH and other major society meetings held throughout 2009. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes.”

7.00 AM-8.00 AM	Registration and breakfast
8.00 AM-8.10 AM	Welcome and introduction
8.10 AM-8.20 AM	Smartest Oncologist/Hematologist Quiz
8.20 AM-8.50 AM	Multiple myeloma: Front-line therapy
8.50 AM-9.20 AM	Multiple myeloma: Relapsed/refractory
9.20 AM-9.50 AM	Indolent non-Hodgkin lymphoma
9.50 AM-10.20 AM	Aggressive non-Hodgkin lymphoma
10.20 AM-10.45 AM	Break
10.45 AM-10.55 AM	Smartest Oncologist/Hematologist Quiz
10.55 AM-11.25 AM	Hodgkin disease
11.25 AM-12.05 PM	Chronic myelogenous leukemia
12.05 PM-12.35 PM	Chronic lymphocytic leukemia
12.35 PM-1.35 PM	Lunch
1.35 PM-1.45 PM	Smartest Oncologist/Hematologist Quiz
1.45 PM-2.15 PM	Myelodysplastic syndromes
2.15 PM-2.45 PM	Myeloproliferative neoplasms
2.45 PM-3.15 PM	Acute leukemia
3.15 PM-3.30 PM	Concluding remarks
3.30 PM	Adjourn

Hagop Kantarjian, MD (Series Chair) The University of Texas M. D. Anderson Cancer Center Houston, Texas Ranjana Advani, MD Stanford University School of Medicine Stanford, California Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, Massachusetts Philip Bierman, MD University of Nebraska Omaha, Nebraska Jorge Cortes, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Guillermo Garcia-Manero, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Irene Ghobrial, MD Dana-Farber Cancer Institute Boston, Massachusetts Fredrick Hagemeister, MD  The University of Texas M. D. Anderson Cancer Center Houston, Texas John P. Leonard, MD Weill Medical College of Cornell University New York, New York Sagar Lonial, MD Emory University Atlanta, Georgia

Vera Malkovska, MD Washington Cancer Institute Washington, DC Peter McLaughlin, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Susan O'Brien, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Gail J. Roboz, MD  Weill Medical College of Cornell University  New York, New York Lewis Silverman, MD Mount Sinai School of Medicine New York, New York Jorge A. Spinolo, MD, FACP Georgia Cancer Specialists Atlanta, Georgia Wendy Stock, MD University of Chicago Chicago, Illinois Ayalew Tefferi, MD Mayo Clinic Rochester, Minnesota Julie Vose, MD University of Nebraska Omaha, Nebraska Meir Wetzler, MD, FACP Roswell Park Cancer Institute Buffalo, New York

New York Kenneth C. Anderson, MD Philip Bierman, MD Jorge Cortes, MD Guillermo Garcia-Manero, MD Irene Ghobrial, MD Hagop Kantarjian, MD (Series Chair) John P. Leonard, MD Susan O'Brien, MD Gail J. Roboz, MD Ayalew Tefferi, MD Julie Vose, MD Washington, DC Ranjana Advani, MD Kenneth C. Anderson, MD Guillermo Garcia-Manero, MD Irene Ghobrial, MD Hagop Kantarjian, MD (Series Chair) Vera Malkovska, MD Peter McLaughlin, MD Susan O'Brien, MD Lewis Silverman, MD Wendy Stock, MD Ayalew Tefferi, MD

Houston Kenneth C. Anderson, MD Philip Bierman, MD Jorge Cortes, MD Guillermo Garcia-Manero, MD Hagop Kantarjian, MD (Series Chair) John P. Leonard, MD Sagar Lonial, MD Susan O'Brien, MD Wendy Stock, MD Ayalew Tefferi, MD Julie Vose, MD Atlanta Kenneth C. Anderson, MD Philip Bierman, MD Jorge Cortes, MD Guillermo Garcia-Manero, MD Fredrick Hagemeister, MD  Hagop Kantarjian, MD (Series Chair) John P. Leonard, MD Sagar Lonial, MD Susan O'Brien, MD Jorge A. Spinolo, MD, FACP Ayalew Tefferi, MD Meir Wetzler, MD, FACP

New York, NY    The Westin New York at Times Square 270 West 43rd Street New York, NY 10036 212-201-2700 Houston, TX Hilton Houston Post Oak 2001 Post Oak Boulevard Houston, TX 77056 713-961-9300

Washington, DC The Westin Washington, DC City Center Hotel 1400 M Street Washington, DC 20005 202-429-1700 Atlanta, GA Renaissance Waverly Hotel 2450 Galleria Parkway Atlanta, GA 30339 770-953-4500

Physicians/Nurses

• Physician preregistration: $75.00
• Physician onsite registration: $100.00
• Nurse preregistration: $35.00*
• Nurse onsite registration: $50.00*

*Supporting documentation of eligibility may be required.



Preregistration will close on the following days for each meeting:

 

• New York – January 20, 2010
• Washington – February 3, 2010
• Houston – February 10, 2010
• Atlanta – February 17, 2010

After preregistration closes, the price will increase to the onsite rate. Attendees may still register online or onsite the morning of the meeting.



Residents/Fellows
Residents/Fellows are eligible for complimentary registration. Please contact hemehighlights@primeoncology.org for more information.


The registration fee includes all program materials, continental breakfast, lunch, and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.



Cancellation/Substitutions Policy
The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

Who Should Attend
This educational activity is intended for hematologists, oncologists, oncology specialist nurses, and other allied healthcare professionals interested in the management of hematologic malignancies.

Statement of Need 
As the rate at which clinical data are released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists, and other physicians involved in the management of hematologic malignancies do not attend major society meetings and, likewise, those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists and hematologists. In addition, the data presented at large clinical conferences are typically not framed in the context of the clinical practice of community oncologists/hematologists. prIME Oncology presents “Hematologic Malignancies Demystified: The Series—A Critical Appraisal of Data from 2009 and ASH,” to review, summarize, and interpret the most clinically significant data released in 2009 in an effort to meet this need.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.
• Explain difficult or unusual problems encountered by the practicing hematologist/oncologist.
• Identify appropriate management options based on emerging data.
• Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies.
• Outline emerging data in the management of multiple hematologic malignancies.
• Explain how to integrate new findings into clinical practice.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 6 AMA PRA Category 1 Credits™ per activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine and prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM and prIME Oncology for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM and prIME Oncology are committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Michael Checkoway prior to the live event at (678) 892-1358 or michael.checkoway@oncoservices.com.